To the full analysis
Zydus Lifesciences stock: growth
ZYDUSLIFE.NSZydus Lifesciences reported $2.89B in revenue for fiscal 2026, up 16.8% on the prior year, up 13.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
15.4%
per year from 2007 to 2026, per share 15%
Earnings (Annual rate)
17.5%
per year from 2007 to 2026, per share 17.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 13.5% | 11.2% | 15.4% |
| Revenue per share | 13.9% | 11.3% | 15.0% |
| Earnings | 18.8% | 10.1% | 17.5% |
| Earnings per share | 18.4% | 10.2% | 17.1% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $189.78M | $24.85M | $1.76M |
| 2008 | $240.85M | $27.38M | −$33.82M |
| 2009 | $304.24M | $32.22M | −$20.01M |
| 2010 | $391.86M | $53.69M | $31.92M |
| 2011 | $474.55M | $75.57M | $19.15M |
| 2012 | $541.01M | $69.36M | −$78.92M |
| 2013 | $670.79M | $69.46M | −$14.18M |
| 2014 | $765.64M | $85.41M | $44.51M |
| 2015 | $919.53M | $122.3M | $51.15M |
| 2016 | $1B | $205.55M | $108.63M |
| 2017 | $996.61M | $158.13M | −$173.1M |
| 2018 | $1.27B | $188.75M | −$13.82M |
| 2019 | $1.4B | $196.51M | $193.97M |
| 2020 | $1.51B | $125.06M | $170.2M |
| 2021 | $1.53B | $226.78M | $259.24M |
| 2022 | $1.61B | $476.95M | $95.82M |
| 2023 | $1.83B | $208.36M | $176.22M |
| 2024 | $2.08B | $410.22M | $246.73M |
| 2025 | $2.47B | $481.01M | $538.26M |
| 2026 | $2.89B | $535.69M | −$127.82M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.